TRCT
PRLD icon

Tower Research Capital (TRC)’s Prelude Therapeutics PRLD Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Buy
+2,377
New +$10.3K ﹤0.01% 3895
2025
Q4 		– Sell
-6,927
Closed -$9.97K – 5485
2025
Q3 		$9.97K Sell
6,927
-9,872
-59% -$9.89K ﹤0.01% 4007
2025
Q2 		$13.6K Buy
16,799
+3,213
+24% +$2.78K ﹤0.01% 3858
2025
Q1 		$10.4K Buy
13,586
+3,210
+31% +$2.99K ﹤0.01% 3637
2024
Q4 		$13.2K Buy
10,376
+5,074
+96% +$6.73K ﹤0.01% 3548
2024
Q3 		$11K Sell
5,302
-1,762
-25% -$8.16K ﹤0.01% 3705
2024
Q2 		$26.9K Buy
7,064
+3,717
+111% +$15.1K ﹤0.01% 3567
2024
Q1 		$15.9K Sell
3,347
-645
-16% -$2.51K ﹤0.01% 3218
2023
Q4 		$17K Buy
3,992
+492
+14% +$1.5K ﹤0.01% 3751
2023
Q3 		$10.8K Buy
3,500
+1,410
+67% +$5.29K ﹤0.01% 4075
2023
Q2 		$9.4K Sell
2,090
-11,262
-84% -$67.3K ﹤0.01% 4290
2023
Q1 		$76K Buy
13,352
+9,820
+278% +$59.9K ﹤0.01% 2120
2022
Q4 		$21K Buy
3,532
+2,278
+182% +$14.6K ﹤0.01% 3099
2022
Q3 		$9K Sell
1,254
-2,770
-69% -$18.7K ﹤0.01% 4678
2022
Q2 		$21K Buy
4,024
+1,689
+72% +$8.6K ﹤0.01% 3752
2022
Q1 		$16K Sell
2,335
-2,985
-56% -$27.3K ﹤0.01% 3766
2021
Q4 		$66K Buy
5,320
+1,821
+52% +$29.6K ﹤0.01% 2543
2021
Q3 		$109K Buy
3,499
+2,434
+229% +$78.8K ﹤0.01% 2332
2021
Q2 		$31K Sell
1,065
-1,740
-62% -$62K ﹤0.01% 3458
2021
Q1 		$122K Buy
2,805
+2,600
+1,268% +$172K ﹤0.01% 2436
2020
Q4 		$15K Buy
+205
New +$10.2K ﹤0.01% 4053

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Tower Research Capital (TRC)'s PRLD Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 2,377 shares worth $12.7K. The stake represents ﹤0.01% of the portfolio and ranks #3895 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in PRLD as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in PRLD in Q4 2020 and has held it in 21 quarters since. The position peaked at $122K in Q1 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Tower Research Capital (TRC) held 2,377 shares of Prelude Therapeutics worth $12.7K as of Q2 2026.
  • Prelude Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3895 holding.
  • Tower Research Capital (TRC) first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Prelude Therapeutics position peaked at $122K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.